Abstract
In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for treating patients with myelofibrosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have